NWAM LLC’s Corvus Pharmaceuticals CRVS Stock Holding History

NWAM LLC’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,500	Closed	-$82.9K	–	520
2024 Q4	$82.9K	Buy	15,500 +5,450	+54%	+$40.7K	0.01%	584
2024 Q3	$53.1K	Buy	+10,050	New	+$36.1K	﹤0.01%	614

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NWAM LLC's CRVS Position: Q1 2025 in Review

NWAM LLC sold out of Corvus Pharmaceuticals (CRVS) in Q1 2025, closing a stake of 15,500 shares — an estimated $82.9K sold.

NWAM LLC first reported a position in CRVS in Q3 2024 and held it in 2 quarters. The position peaked at $82.9K in Q4 2024. 88 funds tracked by Wall St. Rank hold CRVS as of Q1 2025.

NWAM LLC reported no remaining Corvus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
NWAM LLC sold 15,500 Corvus Pharmaceuticals shares in Q1 2025, an estimated $82.9K.
NWAM LLC first reported a position in Corvus Pharmaceuticals in Q3 2024 and held it in 2 quarters.
NWAM LLC's Corvus Pharmaceuticals position peaked at $82.9K in Q4 2024.
88 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2025.

Based on NWAM LLC's 13F filing for Q1 2025, filed 5 May 2025.